WGS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
WGS 近期報酬表現
13.52%
Genedx holdings corp
2.35%
同產業平均
-0.21%
S&P500
與 WGS 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
SEM | Select medical holdings corp | 3 分 | 4 分 | 4 分 | 3 分 | 3 分 | |
JYNT | Joint corp | 3 分 | 5 分 | 4 分 | 3 分 | 1 分 | |
GDRX | Goodrx holdings, inc. | 2 分 | 5 分 | 2 分 | 1 分 | 1 分 | |
ALHC | Alignment healthcare inc | 3 分 | 4 分 | 2 分 | 3 分 | 1 分 | |
PGNY | Progyny inc | 4 分 | 1 分 | 1 分 | 3 分 | 1 分 |
- SEM Select medical holdings corp價值 3 分趨勢 4 分波段 4 分籌碼 3 分股利 3 分查看更多
WGS 公司資訊
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.